Danaher Co. (NYSE:DHR) Shares Acquired by TrinityPoint Wealth LLC

TrinityPoint Wealth LLC boosted its holdings in Danaher Co. (NYSE:DHRFree Report) by 12.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,469 shares of the conglomerate’s stock after purchasing an additional 162 shares during the quarter. TrinityPoint Wealth LLC’s holdings in Danaher were worth $340,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. WealthPlan Investment Management LLC increased its position in Danaher by 100.5% in the third quarter. WealthPlan Investment Management LLC now owns 12,084 shares of the conglomerate’s stock worth $2,998,000 after buying an additional 6,056 shares during the period. NBC Securities Inc. bought a new stake in Danaher in the 3rd quarter valued at about $201,000. Cornerstone Wealth Management LLC bought a new position in Danaher in the 3rd quarter worth about $450,000. Atria Investments Inc increased its stake in shares of Danaher by 3.1% in the third quarter. Atria Investments Inc now owns 38,019 shares of the conglomerate’s stock valued at $9,430,000 after purchasing an additional 1,156 shares during the period. Finally, Financial Counselors Inc. raised its holdings in shares of Danaher by 1.5% during the third quarter. Financial Counselors Inc. now owns 110,549 shares of the conglomerate’s stock valued at $27,427,000 after buying an additional 1,643 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR stock opened at $258.68 on Wednesday. The firm has a 50-day moving average of $250.28 and a two-hundred day moving average of $240.16. The firm has a market capitalization of $191.60 billion, a PE ratio of 43.84, a P/E/G ratio of 4.02 and a beta of 0.83. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. Danaher Co. has a one year low of $182.09 and a one year high of $268.98.

Danaher (NYSE:DHRGet Free Report) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company’s revenue was down 2.6% on a year-over-year basis. During the same quarter last year, the business posted $2.36 EPS. On average, analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.42%. Danaher’s payout ratio is presently 18.31%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Robert W. Baird raised their target price on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Barclays upped their price objective on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. KeyCorp raised their target price on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Bank of America increased their price objective on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a report on Wednesday, April 24th. Finally, StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $267.31.

Read Our Latest Stock Analysis on Danaher

Insider Buying and Selling at Danaher

In related news, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the sale, the chief executive officer now directly owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CFO Matthew Mcgrew sold 46,377 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $7,441,441.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the sale, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The disclosure for this sale can be found here. Insiders have sold a total of 148,783 shares of company stock valued at $37,536,717 in the last 90 days. 10.90% of the stock is currently owned by corporate insiders.

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Further Reading

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.